BIIB - Biogen Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
323.76
-1.88 (-0.58%)
At close: 4:00PM EDT

323.76 0.00 (0.00%)
After hours: 6:35PM EDT

Stock chart is not supported by your current browser
Previous Close325.64
Open326.26
Bid322.23 x 1100
Ask326.00 x 2200
Day's Range322.42 - 327.75
52 Week Range249.17 - 388.67
Volume906,401
Avg. Volume1,295,163
Market Cap63.687B
Beta (3Y Monthly)1.69
PE Ratio (TTM)15.00
EPS (TTM)21.58
Earnings DateApr 24, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est380.14
Trade prices are not sourced from all markets
  • Markit11 hours ago

    See what the IHS Markit Score report has to say about Biogen Inc.

    Biogen Inc NASDAQ/NGS:BIIBView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low Bearish sentimentShort interest | PositiveShort interest is extremely low for BIIB with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting BIIB. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding BIIB are favorable, with net inflows of $11.70 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • TheStreet.comyesterday

    Biogen Could Go Either Way - Mixed Indicators and Charts

    In this daily bar chart of BIIB, below, we can see that prices have been drifting lower from July. The volume histogram right below the price chart is hard to read and interpret but the daily On-Balance-Volume (OBV) line shows a positive trend the past 12 months. The OBV line has been strong from the end of December even while prices have made lower highs - either buyers of BIIB are very skilled and have stopped short of pushing prices up or the rising OBV line has not been strong long enough to tip the scales to the upside.

  • PDL BioPharma (PDLI) Q4 Earnings Top Mark, Revenues Fall Y/Y
    Zacks4 days ago

    PDL BioPharma (PDLI) Q4 Earnings Top Mark, Revenues Fall Y/Y

    PDL BioPharma's (PDLI) earnings exceed estimates in Q4. Lower royalties as well as weak product sales induce a downfall in year-over-year revenues.

  • Top Stock Reports for Visa, Honeywell & Biogen
    Zacks5 days ago

    Top Stock Reports for Visa, Honeywell & Biogen

    Top Stock Reports for Visa, Honeywell & Biogen

  • The Zacks Analyst Blog Highlights: Visa, Honeywell, Biogen, Humana and EOG Resources
    Zacks6 days ago

    The Zacks Analyst Blog Highlights: Visa, Honeywell, Biogen, Humana and EOG Resources

    The Zacks Analyst Blog Highlights: Visa, Honeywell, Biogen, Humana and EOG Resources

  • Fujifilm snaps up Biogen manufacturing site, employees for $890M
    American City Business Journals7 days ago

    Fujifilm snaps up Biogen manufacturing site, employees for $890M

    One of Massachusetts' biotech leaders, Biogen, is unloading one of its manufacturing sites and hundreds of employees to photo and imaging giant Fujifilm.

  • Celgene (CELG) Submits Application for MS Drug in Europe
    Zacks7 days ago

    Celgene (CELG) Submits Application for MS Drug in Europe

    Celgene (CELG) submits application for MS drug, ozanimod to the European Medicines Agency.

  • Japan's Fujifilm buys biologics unit from Biogen to boost healthcare business
    Reuters8 days ago

    Japan's Fujifilm buys biologics unit from Biogen to boost healthcare business

    By Takashi Umekawa TOKYO (Reuters) - Japan's Fujifilm Holdings Corp will buy a drugmaking business from U.S.-based Biogen Inc for about $890 million (674.8 million pounds) to try to bolster its healthcare ...

  • GlobeNewswire8 days ago

    Biogen Enters Into an Agreement to Sell Its Large-Scale Biologics Manufacturing Site in Hillerød, Denmark to Fujifilm

    Biogen (BIIB) today announced that it has entered into a share purchase agreement with FUJIFILM Corporation (Fujifilm) under which Fujifilm will acquire the shares of Biogen’s subsidiary, which holds Biogen’s biologics manufacturing operations in Hillerød, Denmark, for up to $890 million in cash, subject to minimum purchase commitment guarantees and other contractual terms.

  • American City Business Journals8 days ago

    Mass. firms riding bull market to nearly $1 trillion in gains

    The longest bull market in U.S. history turned 10 this past weekend. Here are the Massachusetts public companies that have gained the most in value over the past decade.

  • Better Buy: Amgen vs. Biogen
    Motley Fool9 days ago

    Better Buy: Amgen vs. Biogen

    These cash-flow monsters are trading on the cheap. Which is the better bet for new money today?

  • 6 of the Most Expensive Stocks That Could Go On Sale
    InvestorPlace11 days ago

    6 of the Most Expensive Stocks That Could Go On Sale

    The most expensive stocks often receive a disproportionate share of the coverage in the financial news industry. Since those stocks often emerge from cutting-edge industries, they tend to win investor attention as they often represent the future.Assuming the company earns a profit, they usually get classified as the most expensive stock through their price-to-earnings (P/E) ratio. The average P/E ratio for an S&P 500 company comes in at about 21.4. However, these stocks command much higher P/E ratios, often into the triple digits. Due to their usually phenomenal growth, these stocks can maintain triple-digit multiples for years. * 10 Tech Stocks to Buy Now for 2025 However, high growth rarely lasts forever. While slowing growth rarely makes these equities cheap stocks, it becomes a time when many of the most expensive stocks go on sale. These six equities, which have often become the most expensive stocks in the recent past, appear poised to trade at sale prices:InvestorPlace - Stock Market News, Stock Advice & Trading TipsSource: Shutterstock Chipotle (CMG)Fast-food stocks rarely make it on a list of most expensive stocks, but the success of the healthy fast food trend Chipotle (NYSE:CMG) pioneered has taken that equity to record highs. Not even outbreaks of E. coli or other cases of food poisoning have not permanently derailed its move higher.Today, CMG stock trades at a P/E of 98. Profit growth takes the forward P/E to just under 40. However, I think Chipotle's days of trading at an elevated multiple may end soon. Other fast-food eateries have latched on to the healthy food trend. Restaurants such as Zoe's Kitchen, Modern Market and many others have emerged. Moreover, established brands such as McDonald's (NYSE:MCD) now offer healthier options.Most remain private for now, but as more of these firms launch IPO's, investors will have several healthy fast-food restaurants from which to choose. Wall Street expects Chipotle to increase profits by an average of 24% per year for the next five years. For this reason, I expect a more gradual drop in the P/E ratio. However, over time I think CMG stock will eventually fall to a P/E ratio comparable to that of McDonald's. Since that trend has already begun, I would recommend avoiding CMG stock at these levels.Source: Shutterstock GoDaddy (GDDY)The public may know GoDaddy (NYSE:GDDY) best for Super Bowl commercials. However, it earns revenue as a domain registrar and web hosting service. Despite its thin-moat business, it has managed to acquire 18 million customers and hold 77 million domain names under management. This strategy has helped GDDY stock grow to a P/E ratio of 164 and will bring a 73.3% profit increase this year if Wall Street's forecasts come to fruition.However, I think the weak moat makes profit forecasts untrustworthy. The problem for GDDY is that consumers who want to register a domain or find web hosting have numerous companies from which to choose. Hence, the Super Bowl commercials and the GoDaddy name constitute its entire moat. Moreover, Danica Patrick's retirement from racing has reduced the exposure she brought to the company. If people start to remember that other hosting companies exist, it could lead to a lower market share and reduced profit growth. * 10 Top Pot Stocks 2019 Has to Offer Despite the problems, I think highly of GoDaddy as a company. Achieving this level of earnings growth in a business with almost no moat stands as an impressive feat. However, I think that weak moat means GDDY stock will not stay on the most expensive stocks list for much longer.Source: Shutterstock Ionis Pharmaceuticals (IONS)Ionis (NASDAQ:IONS) specializes in antisense technology. This allows for the manipulation of genes to treat diseases. The company is best known for the drug Spinraza, a therapy which it developed with Biogen (NASDAQ:BIIB) for spinal muscular atrophy. Ionis also leads the way in RNA therapies.Where it cannot seem to lead the way is in stock price growth. IONS stock trades at around $70 per share. This takes it to a record high, but it also means it could form a double-top as it slightly exceeds the record levels in 2015. Moreover, the spike in profits in 2018 occurred from a one-time, $292 million tax event in the fourth quarter. Without such events, the forward P/E ratio rises to just above 201.Analysts predict an average profit growth rate of 40% per year for the next five years. However, with drops in earnings coming for both this year and next, one has to wonder whether that forecast will hold. Even if IONS stock makes or exceeds that profit growth, whether it justifies its high multiple remains in question. While I expect Ionis to develop innovative therapies, measuring how much they succeed remains difficult. Between the possible double top in the charts, a 201 forward P/E and an uncertain future, I find it difficult to stay optimistic about the near-term prospects of IONS stock.Source: Vivian D Nguyen via Flickr (Modified) Netflix (NFLX)As the pioneer in streaming video, Netflix (NASDAQ:NFLX) stock has remained a growth powerhouse for many years. Triple-digit P/E ratios and threats from competing streaming services have failed to stop the growth in NFLX stock. Over the last few years, Netflix has maintained this growth by developing award-winning, popular content and partnering with the likes of Disney (NYSE:DIS) to offer a wide variety of viewing choices.However, Disney now plans to offer its own streaming service. With that, much of its popular content switches from a company asset to a competitive threat. Moreover, the high costs of in-house content development have increased the debt load on Netflix's balance sheet. Netflix has increased fees to mitigate that cost. However, with Disney charging only $4.95 for its ESPN+ streaming services, they could choose to undercut Netflix and diminish the company's ability to increase fees. * 7 Top Stocks to Buy From Goldman Sachs' Secret Portfolio Granted, streaming services are a bargain compared to the traditional pay TV services. For this reason, rising prices may not lead to revenue declines. Still, in a world with many peers, maintaining the high multiple of NFLX stock could become difficult. Moreover, the forward P/E ratio, which now stands at just under 55, has fallen in recent years. This could trigger further stock dilution as Netflix needs options to pay down its debt. I expect Netflix to remain a content powerhouse for years to come, but with rising debts and increased competition, NFLX will probably not stay on the list of most expensive stocks.Source: Shopify via Flickr Shopify (SHOP)I have often referred to Shopify (NYSE:SHOP) stock as the "anti-Amazon," the company that allows one to set up shop without the help of online giant Amazon (NASDAQ:AMZN). Shopify's platform allows any entrepreneur to build and operate an online store with minimal development skills. Given that reality, one can see why it earned its place on many most expensive stocks lists.Since it trades at over 18 times sales and almost ten times book value, most would call SHOP stock pricey. Moreover, factors have emerged that would call these multiples as well as its 216.9 forward P/E ratio into question. Competitors such as WooCommerce and Magento, a product owned by Adobe (NASDAQ:ADBE) offer credible alternative platforms to online entrepreneurs. Amazon and Square (NYSE:SQ) have also targeted its customer base.Wall Street expects average earnings increases of 56.3% per year over the next five years. Also, all e-commerce platform developers should benefit from the massive growth the industry will enjoy for the foreseeable future. However, Shopify has yet to turn an annual profit. With all of the available alternatives, more investors will probably question the current valuation of SHOP stock.Source: Web Summit Via Flickr Twilio (TWLO)Twilio (NYSE:TWLO) has earned its designation among the most expensive stocks with its forward P/E ratio of almost 430. TWLO dominates the platform-as-a-service (PaaS) for cloud-based APIs. In layman's terms, this is the technology that enables firms such as Uber to operate their services.Although analysts foresee profits falling this year, they believe earnings will grow by an average 36.5% per year over the next five years. I think this rate of increase deserves a higher-than-average multiple. However, this growth rate still cannot possibly justify a 430 forward P/E multiple.Moreover, competition has become an increasing threat as smaller competitors have emerged. TWLO stock fell recently when news came out that Uber was looking to reduce its dependence on Twilio. The stock could also drop precipitously if companies such as Amazon (who serves as Twilio's hosting company) or Alphabet (NASDAQ:GOOG, NASDAQ:GOOGL) decide to enter this market. * 7 Dividend Stocks Already Rewarding Shareholders In 2019 No matter the size of Twilio's direct peers, competition will pose an increasing threat. I expect this industry to see massive growth over the next few years. However, even exponential growth has its limits. With its 400-plus forward P/E and new competitors emerging, I think TWLO stock has nowhere to go but down.As of this writing, Will Healy did not hold a position in any of the aforementioned stocks. You can follow Will on Twitter at @HealyWriting. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Dividend Stocks Already Rewarding Shareholders In 2019 * The 10 Best-Performing ETFs This Year * 7 Stocks That Should Be Worried About a Data Dividend Compare Brokers The post 6 of the Most Expensive Stocks That Could Go On Sale appeared first on InvestorPlace.

  • Motley Fool11 days ago

    Gene Therapy M&A Has Shares Skyrocketing -- Could This Company Be Next?

    Roche and Biogen are spending big bucks on gene therapy biotech stocks.

  • Biotech Stock Roundup: BIIB to Acquire Nightstar, Other Pipeline News & More
    Zacks13 days ago

    Biotech Stock Roundup: BIIB to Acquire Nightstar, Other Pipeline News & More

    Key highlights of the past week are merger agreements plus regulatory and pipeline developments.

  • Investing.com14 days ago

    Biotech Companies Slump Midday With FDA Chief Set to Leave

    Gottlieb said in a letter addressed to the agency that he is leaving to be with family.

  • Biogen to Acquire Gene-Therapy Company Nightstar for $800M
    Zacks14 days ago

    Biogen to Acquire Gene-Therapy Company Nightstar for $800M

    Biogen (BIIB) to acquire gene-therapy company, Nightstar Therapeutics to accelerate entry into ophthalmology space.

  • How Much Does Biogen Gain From Its $800 Million Gene Therapy Buyout?
    Investor's Business Daily14 days ago

    How Much Does Biogen Gain From Its $800 Million Gene Therapy Buyout?

    Biogen's pending acquisition of gene therapy player Nightstar Therapeutics only offers a "modest pipeline boost," an analyst said Tuesday. Nightstar is working on therapies for eye diseases.

  • Benzinga14 days ago

    Analysts Laud Biogen's M&A Strategy Following Deal to Buy Gene Therapy Company Nightstar

    Biogen Inc (NASDAQ: BIIB ) announced Monday a deal to buy gene therapy biotech Nightstar Therapeutics PLC (NASDAQ: NITE ) for $800 million. The Analysts Baird analyst Brian Skorney maintained a Neutral ...

  • Company News For Mar 5, 2019
    Zacks14 days ago

    Company News For Mar 5, 2019

    Companies in the news are; PLCE, BIIB, NITE, ASND and TAK

  • Stock Market Today: Biogen Buys Gene Therapy Company Nightstar Therapeutics
    Motley Fool15 days ago

    Stock Market Today: Biogen Buys Gene Therapy Company Nightstar Therapeutics

    Elsewhere, Village Farms jumps into the U.S. hemp market.

  • Biogen Shores Up Gene Therapy Assets With $800 Million Takeover
    Investor's Business Daily15 days ago

    Biogen Shores Up Gene Therapy Assets With $800 Million Takeover

    Nightstar Therapeutics soared early Monday after Biogen pledged to spend $800 million to buy the gene therapy firm. The smaller biotech is working on gene therapies in rare eye diseases.

  • Ionis Pharmaceuticals Funds Its Pipeline of More Than 40 Drugs
    Motley Fool15 days ago

    Ionis Pharmaceuticals Funds Its Pipeline of More Than 40 Drugs

    The biotech turned an operating profit in the fourth quarter thanks to revenue from partners.

  • NITE, BIIB: Nightstar Therapeutics Stock Soars on Biogen Buy
    InvestorPlace15 days ago

    NITE, BIIB: Nightstar Therapeutics Stock Soars on Biogen Buy

    Nightstar Therapeutics stock was soaring on Monday following news that Biogen (NASDAQ:BIIB) is acquiring it.Source: Biogen via YouTubeThe deal will have Biogen spending a total of $877 million to acquire Nightstar Therapeutics (NASDAQ:NITE). This will have the company paying $25.50 in cash for each share of Nightstar Therapeutics stock.The offer price of $25.50 per share for Nightstar Therapeutics stock represents a 70% premium to the stock's 30 trading day volume-weighted average price. It is also a 68% premium over the stock's closing price from Friday.InvestorPlace - Stock Market News, Stock Advice & Trading TipsBiogen notes that all issued and to be issued shares of Nightstar Therapeutics stock will be acquired by Tungsten Bidco Limited. This is a newly-incorporated company and wholly-owned subsidiary of BIIB."I am proud of Nightstar's achievements, delivering two proof-of-concept programs and building a world class organisation," Chris Hollowood, Chairman of Nightstar Therapeutics, said in a statement. "We look forward to seeing the next chapter of Nightstar's journey under Biogen's ownership, as it works to achieve its ultimate ambition of delivering transformational treatments to patients."Biogen and Nightstar Therapeutics are expecting the acquisition deal to close during mid-2019. However, it will first have to get regulatory approval and complete other customary closing conditions. Among these is approval from holders of Nightstar Therapeutics stock for the deal. The acquisition does not need approval from shareholders of BIIB. * 7 Top-Rated Stocks to Buy for March Nightstar Therapeutics is getting its financial advice for the deal from Centerview Partners and Jefferies LLC. The company's legal advice concerning the matter is coming from Arps, Slate, Meagher & Flom LLP.Nite stock was up 66% and BIIB stock was down 2% as of noon Monday. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 5 Retail Stocks Ready to Break Out * 7 Strong Buy Stocks the Street Loves * 10 Best Stocks to Buy and Hold Forever As of this writing, William White did not hold a position in any of the aforementioned securities.Compare Brokers The post NITE, BIIB: Nightstar Therapeutics Stock Soars on Biogen Buy appeared first on InvestorPlace.

  • Barrons.com15 days ago

    Nightstar Stock Is Latest Winner From Gene-Therapy Gold Rush

    Biogen is buying Nightstar Therapeutics at a 68% premium to the British company’s closing price on Friday.